Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a pharmaceutical manufacturing company listed on the Shenzhen Stock Exchange since 2015. The company specializes in the research and development, production, and sales of a wide range of pharmaceuticals, including biologics, patent Chinese medicines, and chemical drugs, as well as medical devices, with a focus on ophthalmic applications. The company's main business lines encompass a diverse portfolio of marketed products, including Conbercept Ophthalmic Injection, Lifitegrast, and various eye drops and capsules. Chengdu Kanghong is recognized for its advanced R&D capabilities, which include key technologies in biopharmaceutical industrialization, synthetic biology, and standardized quality control for patent Chinese medicines. The company is committed to continuous innovation and has established a strong market position through its substantial production capacity, talented workforce, and expanding international presence.

Building on over three decades of experience, the company is entering a period of high-quality development. This growth is fueled by our strategic planning and continuous innovation, resulting in significant competitive advantages. These advantages are evident in our strong portfolio of marketed products, robust research pipeline, advanced R&D capabilities, substantial production capacity, talented team, expanding international presence, and well-established brand.